30 Apr Cipla-Pioglitazone Hydrochloride 15 (Pioglitazone Hydrochloride)
| Company name & Address: | registration number | Batch number(s) | Expiry date | Pack size | First release date | Re-call Classification | Recall date |
| Cipla Medpro (Pty) Ltd
Building 2 Junxion Park 10 Elephant Lane Century City South Africa 7441 |
A40/21.2/0149 |
4GC0350 GC30719 |
February 2027 July 2026 |
30s |
06 August 2024 30 November 2023 |
Class II Type B |
20.April.2026 |
Brief description of the problem (reason for recall)
This recall is initiated because of a dissolution failure observed in ongoing stability monitoring batches.
Advise for health professionals and distributors:
We request that you refrain from selling or dispensing any pack of the affected batches of Cipla-Pioglitazone 15 and return them to your supplying warehouse or distributor with immediate effect. Cipla Medpro (Pty) Ltd. will collect all your stock which will be credited / replaced. For further product information, please call Cipla Medpro (Pty) Ltd. via their Customer Care line (080 222 6662).
Proposed action taken and its urgency: A SAHPRA approved recall letter was distributed to all distribution points and the recall process was initiated.
Reporting side effects
Public and healthcare professionals are encouraged to report any side effects after using a health product or after immunisation by using the Med Safety App. Your report will contribute to our monitoring of these health products.